While the specific length of treatment depends on your plan with your doctor, it appears that GLP-1s should be used longterm to maintain weight loss
NHS provision of Wegovy is highly restricted following NICE guidance (TA875), limited to specialist weight management services for adults with BMI 35 kg/m (or 32.5 kg/m for certain ethnic groups) and at least one weight-related comorbidity
ERR agonism the primary driver ERR is highly expressed in energy-demanding tissues such as skeletal muscle, heart, brown adipose tissue, and liver
By extrapolation from the established profiles of approved GLP-1 receptor agonists including semaglutide (Wegovy SmPC, MHRA/EMC) and tirzepatide (Mounjaro SmPC, MHRA/EMC) clinicians should anticipate the need to review and potentially reduce antihypertensive doses as significant weight loss occurs, in line with BNF and NICE guidance principles
And also, I have noticed since I added, I mean, what did I add that wasn't here before
Villarroya J, Cereijo R, Gavalda-Navarro A, Peyrou M, Giralt M, Villarroya F